What is WO2013182972 regarding daridorexant?
Patent application WO2013182972 describes compounds and their use in treating sleep disorders. Specifically, it claims novel compounds that act as dual orexin receptor antagonists (DORAs) and provides methods for their synthesis and pharmaceutical formulation. These compounds are intended for use in the treatment of insomnia and other conditions characterized by excessive daytime sleepiness or sleep-wake cycle disturbances [1].
When does daridorexant patent protection expire?
The patent family associated with WO2013182972 is part of the broader intellectual property landscape for daridorexant. Exclusivity for specific daridorexant patents can vary by region. For example, in the United States, the primary patents related to daridorexant, including those stemming from this application, are expected to expire around 2033, though this can be subject to extensions and potential challenges [2].
How does daridorexant work?
Daridorexant functions by blocking the action of orexin neuropeptides. Orexins are signaling molecules in the brain that play a crucial role in promoting wakefulness. By inhibiting the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R), daridorexant reduces the signaling that promotes wakefulness, thereby facilitating sleep [1].
What are the potential risks or side effects of daridorexant?
While specific clinical trial data is not detailed in the patent application, drugs in the DORA class, including daridorexant, can carry risks such as somnolence, which may impair daytime functioning. Patients are advised to avoid driving or operating heavy machinery until they know how daridorexant affects them. Other reported side effects can include headache and fatigue. A significant safety concern for this class of drugs is the risk of central nervous system depression, which could be exacerbated by alcohol or other sedating substances [3].
Who developed daridorexant and holds the patent?
The patent application WO2013182972 lists Idorsia Pharmaceuticals Ltd. as the applicant. Idorsia Pharmaceuticals is the company that developed daridorexant, marketed as Quviviq, for the treatment of insomnia [1][4].
How does daridorexant compare to other insomnia treatments?
Daridorexant represents a different mechanism of action compared to traditional insomnia medications like benzodiazepines or non-benzodiazepine hypnotics (e.g., zolpidem). These older classes of drugs generally work by enhancing the effects of the inhibitory neurotransmitter GABA. Daridorexant, as a DORA, targets the wakefulness-promoting orexin system, offering a distinct approach to managing insomnia without the GABAergic pathway [1][3].
What is the regulatory status of daridorexant?
Daridorexant has received regulatory approval in several major markets. In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of insomnia in adults [4]. Similar approvals have been granted in other regions, such as Europe by the European Medicines Agency (EMA) [3].
Sources:
[1] https://patents.google.com/patent/WO2013182972A1/
[2] DrugPatentWatch.com
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-2022